[HTML][HTML] Nanocarrier-based drug combination therapy for glioblastoma
M Zhao, D van Straten, MLD Broekman, V Préat… - Theranostics, 2020 - ncbi.nlm.nih.gov
The current achievements in treating glioblastoma (GBM) patients are not sufficient because
many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem …
many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem …
Sex-specific differences in glioblastoma
Sex differences have been well identified in many brain tumors. Even though glioblastoma
(GBM) is the most common primary malignant brain tumor in adults and has the worst …
(GBM) is the most common primary malignant brain tumor in adults and has the worst …
Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel
Tumours with an immunosuppressive microenvironment respond poorly to therapy.
Activation of the stimulator of interferon genes (STING) pathway can enhance intratumoural …
Activation of the stimulator of interferon genes (STING) pathway can enhance intratumoural …
High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme
P Kadiyala, D Li, FM Nuñez, D Altshuler, R Doherty… - ACS …, 2019 - ACS Publications
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor, for which there is no
cure. Treatment effectiveness for GBM has been limited due to tumor heterogeneity, an …
cure. Treatment effectiveness for GBM has been limited due to tumor heterogeneity, an …
Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
The immunosuppressive effects of chemotherapy present a challenge for designing effective
cancer immunotherapy strategies. We hypothesized that although systemic chemotherapy …
cancer immunotherapy strategies. We hypothesized that although systemic chemotherapy …
Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
Immune checkpoint blockers (ICBs) have shown great promise at harnessing immune
system to combat cancer. However, only a fraction of patients can directly benefit from the …
system to combat cancer. However, only a fraction of patients can directly benefit from the …
Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology.
BC Özdemir, C Csajka, GP Dotto… - Journal of clinical …, 2018 - europepmc.org
Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the
Era of Precision Oncology. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …
Era of Precision Oncology. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …
Keep a watchful eye on methionine adenosyltransferases, novel therapeutic opportunities for hepatobiliary and pancreatic tumours
P Yang, J Jiao, Z Chen, X Zhu, C Cheng - Biochimica et Biophysica Acta …, 2022 - Elsevier
Methionine adenosyltransferases (MATs) synthesize S-adenosylmethionine (SAM) from
methionine, which provides methyl groups for DNA, RNA, protein, and lipid methylation …
methionine, which provides methyl groups for DNA, RNA, protein, and lipid methylation …
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma
E Le Rhun, FB Oppong, M Vanlancker, R Stupp… - Neuro …, 2022 - academic.oup.com
Background Myelosuppression is the major toxicity encountered during temozolomide
chemoradiotherapy for newly diagnosed glioblastoma. Methods We assessed the …
chemoradiotherapy for newly diagnosed glioblastoma. Methods We assessed the …
[HTML][HTML] Gender and sex disparity in cancer trials
E Lee, P Wen - ESMO open, 2020 - Elsevier
The study population within phase III clinical trials leading to approval of new cancer agents
should ideally more closely mirror the population who will ultimately receive these agents …
should ideally more closely mirror the population who will ultimately receive these agents …